Top Performing Drug – Enbrel (June Edition)
PharmaShots
JUNE 28, 2023
Consistent with prior periods, Enbrel continued to lose market share, and this decline was compounded by a reduction in the growth rate of the rheumatology market as a result of COVID-19. Generally, these reviews are helpful when consumers research the product and read multiple reviews before buying it.
40 
Let's personalize your content